Showing results (641-650 of 1,074) with videos related to

Sort By:
Pageof 108
Therapeutic Advances in Neurological Disorders|March 30, 2023
Retrospective cohort study to devise a treatment decision score predicting adverse 24-month radiological activity in early multiple sclerosisAlexander Hapfelmeier, Begum Irmak On, Mark Mühlau, et al.
Therapeutic Advances in Neurological Disorders|April 3, 2023
Comparison of IVIg and TPE efficacy in the treatment of neurological disorders: a systematic literature reviewAshwin A Pinto, Jerome De Seze, Anu Jacob, et al.
Therapeutic Advances in Neurological Disorders|April 28, 2023
The severity of corneal nerve loss differentiates motor subtypes in patients with Parkinson's diseaseNing-Ning Che, Qiu-Huan Jiang, Shuai Chen, et al.
Therapeutic Advances in Neurological Disorders|December 25, 2023
Defining the course of neurosarcoidosis according to presentation at onset and disease modifying treatment: a cohort study of 84 patientsInès Bekkour, Edouard Courtin, Cécile Dulau-Metras, et al.
Therapeutic Advances in Neurological Disorders|March 27, 2024
Patisiran exposure in early pregnancy: a case reportValentin Loser, Thomas Baumgartner, Hélène Legardeur, et al.
Therapeutic Advances in Neurological Disorders|March 25, 2024
Comparative efficacy of ofatumumab versus oral therapies for relapsing multiple sclerosis patients using propensity score analyses and simulated treatment comparisonsNicholas Riley, Christopher Drudge, Morag Nelson, et al.
Therapeutic Advances in Neurological Disorders|February 28, 2024
Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapiesHelmut Butzkueven, Tomas Kalincik, Francesco Patti, et al.
Therapeutic Advances in Neurological Disorders|November 13, 2023
Feasibility of home dose optimization of apomorphine sublingual film in Parkinson's disease patients with OFF episodes: results from the dose-optimization phase of an open-label, randomized crossover studyJan Kassubek, Fabrizio Stocchi, Ernest Balaguer Martinez, et al.
Therapeutic Advances in Neurological Disorders|November 13, 2023
Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosisKimberley Allen-Philbey, Stefania De Trane, Amy MacDougall, et al.
Therapeutic Advances in Neurological Disorders|August 20, 2024
Management of delirium in acute stroke patients: a position paper by the Austrian Stroke Society on prevention, diagnosis, and treatmentMarkus Kneihsl, Natalie Berger, Stefan Sumerauer, et al.
Pageof 108